Background: The data on medium-term follow-up of coronavirus disease-19 (COVID-19) pneumonia survivors is scarce Medium-term follow-up will generate knowledge and help in devising a structured follow-up plan and to facilitate enrolment in clinical trials assessing the role of antifibrotic drugs in modifying the course of disease in order to avert long-term pulmonary sequelae of disease The study was aimed to evaluate the lung findings on a medium-term follow-up (3 months or more) chest computed tomography (CT) in COVID-19 pneumonia survivors, assess the rate of resolution or persistence of lung abnormalities and to identify the initial demographic, clinical, and imaging characteristics that could potentially predict the persistence of lung abnormalities on follow-up Results: Out of the total study cohort of 81 patients, 46 (56 8%) demonstrated complete resolution of lung findings and the remaining 35 (43 2%) had residual lung opacities on follow-up CT The most common type of residual abnormality was ground glass opacity (GGO) (16/35;45 7%), followed by parenchymal bands (9/35;25 7%), mixed pattern of GGO and parenchymal bands (6/35;17 2%), bronchiectasis (6/35;17 2%), and interlobular septal thickening (4/35;11 4%) Patients with residual abnormalities were older, had higher BMI, more comorbidities, lower SpO2, longer hospital stay, higher rate of intensive care unit (ICU) admission, higher WBC count, a higher CT severity score, and lower rate of steroid administration with all p values &lt; 0 05 Conclusion: Nearly half of post-COVID-19 survivors had residual lung abnormalities after ≥ 3 months of follow-up Certain clinico-radiological characteristics have the potential to identify the individuals at risk of having residual lung abnormalities on medium-term follow-up © 2021, The Author(s)
Medium-term chest computed tomography (CT) follow-up of COVID-19 pneumonia patients after recovery to assess the rate of resolution and determine the potential predictors of persistent lung changes